Vaxcyte develops next-generation pneumococcal vaccines.
Vaxcyte, Inc. (PCVX) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 16:08 ET. Consensus EPS estimate is $-2.12.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2025-11-04 | FY2025 Q3 | $-1.27 | $-1.56 | -22.8% | $0 |
| 2025-08-06 | FY2025 Q2 | $-1.12 | $-1.22 | -8.9% | $0 |
| 2025-05-07 | FY2025 Q1 | $-1.02 | $-1.04 | -2.0% | $0 |
| 2025-02-25 | FY2024 Q4 | $-1.16 | $-1.12 | +3.4% | $0 |
| 2024-11-05 | FY2024 Q3 | $-1.10 | $-0.83 | +24.5% | $0 |
| 2024-08-06 | FY2024 Q2 | $-0.98 | $-1.10 | -12.8% | $0 |
| 2024-05-08 | FY2024 Q1 | $-1.13 | $-0.85 | +24.8% | $0 |
| 2024-02-27 | FY2023 Q4 | $-0.90 | $-1.73 | -92.2% | $0 |
PCVX has beaten consensus EPS in 3 of its last 8 reported quarters.
See PCVX on the live calendar →